Literature DB >> 27352069

Outpatient therapeutic chronic opioid consumption in Italy: a one-year survey.

Luca Miceli1, Rym Bednarova2, Miriam DI Cesare3, Elisabetta Santori3, Marco Spizzichino3, Lidia DI Minco3, Renato Botti3, Massimo Casciello3, Giorgio Della Rocca4.   

Abstract

BACKGROUND: In Italy since the 38/2010 law concerning Palliative Care and pain therapy has been promulgated, the consumption of opioids started increasing. However, despite the availability of a large amount of data regarding opioid prescription, a database including all patients on chronic opioid therapy does not yet exist.
METHODS: Retrospective analysis of analgesic opioid consumption was performed between January 2013 and December 2013 using the data of national refunded medications for outpatients, collected by Italian Ministry of Health. We considered patients on chronic opioid therapy those patients with at least three opioids prescriptions in three consecutive months and/or six opioid prescriptions in six even not consecutive months in the observation period. We considered cancer patients those with neoplasm exemption code in the scheduled prescription and/or patients with at least one ROOs prescription (rapid onset opioids, approved in Italy for Break Through cancer Pain-BTcP- only). We also calculated the patient's morphine daily mean dose (MED) converting all prescribed opioids in equivalent of morphine using specific conversion tables.
RESULTS: This census revealed a total of 422,542 patients in chronic therapy with opioids, of those 369.961 with chronic non-cancer pain and 52,581 with chronic cancer pain. This represents about 4% of the estimated requirement in Italy for both groups based on previous surveys regarding the prevalence of chronic pain.
CONCLUSIONS: Relatively to MED, We found that in Italy chronic cancer pain patients receive doses similar to patients with cancer pain in other Literature reports, whereas patients with chronic non-cancer pain received lower dosages.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27352069     DOI: 10.23736/S0375-9393.16.11099-5

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  5 in total

1.  The Potential of Big Data Research in HealthCare for Medical Doctors' Learning.

Authors:  Manuel Au-Yong-Oliveira; Antonio Pesqueira; Maria José Sousa; Francesca Dal Mas; Mohammad Soliman
Journal:  J Med Syst       Date:  2021-01-07       Impact factor: 4.460

2.  Assessment of Pain and Associated Comorbidities: A Survey of Real Life Experiences Among Nurses in Italy.

Authors:  Chiara Angeletti; Paolo Matteo Angeletti; Martina Paesani; Cristiana Guetti; Aglaia Gyra; Gianluca Perseo; Alessandra Ciccozzi; Franco Marinangeli; Emma Altobelli
Journal:  J Pain Res       Date:  2021-01-25       Impact factor: 3.133

3.  Self-Reported Practices and Emotions in Prescribing Opioids for Chronic Noncancer Pain: A Cross-Sectional Study of German Physicians.

Authors:  Erika Schulte; Frank Petzke; Claudia Spies; Claudia Denke; Michael Schäfer; Norbert Donner-Banzhoff; Ralph Hertwig; Odette Wegwarth
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.241

Review 4.  Opioid Misuse: A Review of the Main Issues, Challenges, and Strategies.

Authors:  Helena Biancuzzi; Francesca Dal Mas; Valerio Brescia; Stefano Campostrini; Marco Cascella; Arturo Cuomo; Lorenzo Cobianchi; Ander Dorken-Gallastegi; Anthony Gebran; Haytham M Kaafarani; Franco Marinangeli; Maurizio Massaro; Angela Renne; Giacomo Scaioli; Rym Bednarova; Alessandro Vittori; Luca Miceli
Journal:  Int J Environ Res Public Health       Date:  2022-09-17       Impact factor: 4.614

Review 5.  Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.

Authors:  Roberto De Giorgio; Furio Massimino Zucco; Giuseppe Chiarioni; Sebastiano Mercadante; Enrico Stefano Corazziari; Augusto Caraceni; Patrizio Odetti; Raffaele Giusti; Franco Marinangeli; Carmine Pinto
Journal:  Adv Ther       Date:  2021-06-04       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.